



NEONATAL MEDICATION PROTOCOLS

MYLANTA
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	MYLANTA
PRESENTATION:	Oral suspension Each 10mL contains: Magnesium Hydroxide 400mg Aluminium Hydroxide (dried) 400mg Simethicone 40mg
ACTION & INDICATION:	Antacid for the prevention and treatment of gastrointestinal haemorrhage.
DOSE :	0.5mL/kg/dose 4 hourly
ADMINISTRATION:	Oral
ADVERSE EFFECTS:	Hypermagnesaemia - monitor serum magnesium with prolonged use.
COMMENTS:	May decrease absorption of oral medications. Separate from other drug administration by two hours. Refrigerate suspension. Discard 6 months after opening
REFERENCES:	Paediatric Pharmacopoeia 13 th Ed Royal Children's Hospital Melbourne
DATE:	October 2013